Oftan (Timolol Maleate)

Timolol Maleate, the active ingredient in Oftan, is a beta‑adrenergic blocker presented as an ophthalmic solution for topical ocular use. It lowers intra‑ocular pressure in patients with glaucoma or ocular hypertension.

GNH USA supplies Oftan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Timolol Maleate is a non‑selective beta‑blocker used to manage ocular pressure in glaucoma and related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression - Ocular hypertension: lowers pressure to prevent conversion to glaucoma - Secondary glaucoma: helps control pressure when caused by other eye conditions

Timolol ophthalmic solution may cause a range of ocular and systemic reactions.

Common Side Effects: - Burning or stinging sensation in the eye - Transient blurred vision - Dry eye or reduced tear production - Conjunctival hyperemia (redness) - Temporary foreign‑body sensation - Mild headache

Serious or Rare Side Effects: - Severe bradycardia or heart block - Systemic hypotension - Bronchospasm or worsening asthma - Allergic reactions (rash, swelling, anaphylaxis) - Marked hypoglycaemia in diabetic patients - Depression or mood changes

Timolol ophthalmic solution requires careful assessment before use.

- Cardiovascular assessment: avoid in patients with uncontrolled bradycardia or heart block - Respiratory screening: use with caution in asthma or COPD - Blood‑glucose monitoring: may mask hypoglycaemia symptoms in diabetics - Concomitant non‑selective beta‑blockers: risk of additive systemic effects - Pregnancy and lactation: prescribe only if benefit outweighs potential risk - Store at ambient temperature: keep below 25 °C, protect from moisture and light

Timolol may interact with several systemic and ocular agents.

Major Interactions (Avoid): - Other non‑selective beta‑blockers: additive systemic beta‑blockade - Calcium channel blockers (verapamil, diltiazem): may enhance bradycardia - Antidiabetic drugs (insulin, sulfonylureas): may mask hypoglycaemia

Moderate Interactions (Monitor Closely): - Topical anesthetics: may increase ocular irritation - Other ocular hypotensive agents (prostaglandin analogues): monitor intra‑ocular pressure response - Systemic antihypertensives: watch for excessive blood‑pressure reduction